Teva Pharmaceutical Industries Ltd. Press Releases https://ir.tevapharm.com/generated by Q4Sat, 06 Jun 2026 15:35:56 -0400Copyright Q4 Inc. All rights reserved.Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Choreab7b3c0da-46d3-4fd3-9bb1-f64862b9f635https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Presents-New-Data-on-AUSTEDO-deutetrabenazine-tablets-and-AUSTEDO-XR-deutetrabenazine-extended-release-tablets-that-Show-Patient--and-Caregiver-Reported-Improvements-in-Huntingtons-Disease-Chorea/default.aspxFri, 05 Jun 2026 11:30:00 -0400Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®77ae54ab-bc27-4d80-ade1-970bf5bb2f5ahttps://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Expands-European-biosimilars-portfolio-with-launch-ofAHZANTIVEaflibercept-biosimilar-to-Eylea/default.aspxThu, 04 Jun 2026 08:30:00 -0400Teva to Present at the Goldman Sachs Global Healthcare Conference69e9ff98-84ff-4d85-b78b-1f3c7c2072abhttps://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Present-at-the-Goldman-Sachs-Global-Healthcare-Conference/default.aspxMon, 01 Jun 2026 16:30:00 -0400The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults8aeda1ed-d9f4-41bc-a3e9-20ccad5840fdhttps://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/The-European-Medicines-Agency-Accepts-Tevas-Marketing-Authorization-Application-for-Olanzapine-Long-Acting-Injectable-TEV-749-for-the-Treatment-of-Schizophrenia-in-Adults/default.aspxThu, 21 May 2026 12:30:00 -0400Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Executione9c02e72-42f9-41a5-895d-2bd51d655786https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Fitch-Upgrades-Teva-to-Investment-Grade-Amid-Pivot-to-Growth-Execution/default.aspxMon, 18 May 2026 08:30:00 -0400Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact08f46be2-e3ff-41cc-868c-87cbcff12142https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Study-Finds-Only-23-of-Younger-Adults-with-Mood-Disorders-and-Tardive-Dyskinesia-TD-Symptoms-Are-Formally-Diagnosed-with-TD-Despite-Widespread-Impact/default.aspxMon, 18 May 2026 08:00:00 -0400Teva to Present at the BofA Securities Health Care Conference9bbfcd80-c7c0-4ffe-8fab-07ee499ab9e1https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Present-at-the-BofA-Securities-Health-Care-Conference/default.aspxMon, 04 May 2026 16:30:00 -0400Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targetsee54a1ee-2c41-4aad-b98f-cc6ef4ea86f1https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Tevas-2025-Healthy-Future-Report-Highlights-Environmental-and-Access-to-Medicines-Progress-Including-Meeting-All-Sustainability-Linked-Bond-Targets/default.aspxThu, 30 Apr 2026 08:30:00 -0400Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution7bcedf05-43dd-427a-91d6-63c0e05c4fe1https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Delivers-Strong-Q1-2026-Results-Driven-by-Innovative-Portfolio-Growth-and-Disciplined-Execution/default.aspxWed, 29 Apr 2026 07:00:00 -0400Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy6fddd6ad-aa0b-46e7-9703-66e55f2700e6https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-AcquireEmalexBiosciences-Adding-NDA-Ready-First-in-Class-Therapy-to-Neuroscience-Pipeline-and-Accelerating-Tevas-Pivot-to-Growth-Strategy/default.aspxWed, 29 Apr 2026 06:30:00 -0400